Trastuzumab deruxtecan: a promising agent for treating HER2-low breast cancer?

• Date :
• 8    
  0

Novel tools for tumor microenvironment analysis in TNBC

• Date :
• 6    
  0

Brain metastases in HER2+ breast cancer

• Date :
• 1    
  0

Adjuvant treatment for stage I HER2+ breast cancer

• Date :
• 0    
  0

Where does immuno-oncology fit in the treatment landscape of TNBC?

• Date :
• 0    
  0

Impact of genomic tools on decision making in breast cancer

• Date :
• 0    
  0

The BCI prognostic model for late relapse breast cancer

• Date :
• 0    
  0

ADCs for HER2+ and HER2-low breast cancer

• Date :
• 0    
  0

The increasing incidence of breast cancer in Asia

• Date :
• 0    
  0

IO-IO combinations in metastatic TNBC

• Date :
• 0    
  0

Future role of immunotherapy in HER2+ breast cancer

• Date :
• 0    
  0

Ethnic differences in hereditary breast cancer

• Date :
• 0    
  0

TLR4 & pSTAT3 expression on CTCs in metastatic breast cancer

• Date :
• 0    
  0

25-year benefit from tamoxifen by clinically used breast cancer markers

• Date :
• 0    
  0

MIMOSA: monalizumab and trastuzumab in HER2+ breast cancer

• Date :
• 0    
  0

CTCs, EMT & immunosuppresive cells in metastatic breast cancer

• Date :
• 0    
  0

Highlights from ESMO Breast 2021

• Date :
• 0    
  0

Dato-DXd: a new ADC on the block

• Date :
• 0    
  0

PTEN protein and gene expression as a biomarker in breast cancer

• Date :
• 0    
  0

ESMO Breast 2021 highlights: biomarker updates

• Date :
• 0    
  0

Real-world use of bevacizumab in patients with breast cancer

• Date :
• 0    
  0

Potential new drugs with activity in metastatic TNBC

• Date :
• 0    
  0

CDK4/6 inhibitors in early stage HR+/HER2- disease

• Date :
• 0    
  0

Men with breast cancer: biology and diagnosis in Eastern Europe

• Date :
• 0    
  0

Optimal chemotherapy combinations in TNBC gBRCA subtypes

• Date :
• 0    
  0

Sequencing therapies in HER2+ breast cancer

• Date :
• 0    
  0

Treating CNS metastases in HER2+ breast cancer

• Date :
• 0    
  0

ROSALINE: targeting ROS1 in combination with ET for breast cancer

• Date :
• 0    
  0

The role of epigenetics in breast cancer

• Date :
• 0    
  0

Racial diversity in FDA registration trials for breast cancer

• Date :
• 0    
  0

Improving enrolment diversity in clinical trials for breast cancer

• Date :
• 0    
  0

ESMO Breast 2021 highlights

• Date :
• 0    
  0

ESMO Breast 2021: What to expect?

• Date :
• 0    
  0

E-cadherin inactivation by Trop-2 drives metastases in TNBC

• Date :
• 0    
  0

Talazoparib in locally advanced or metastatic breast cancer

• Date :
• 0    
  0

Treating BRCA1 and BRCA2 breast cancer

• Date :
• 0    
  0

BrainStorm: improving prediction, diagnosis and management of brain metastases

• Date :
• 0    
  0

Abemaciclib for HR+/HER2- advanced or metastatic breast cancer

• Date :
• 0    
  0

Highlights from ESMO Breast 2021

• Date :
• 0    
  0

The MIMOSA trial and a novel prognostic factor in breast cancer

• Date :
• 0    
  0

Decision-making in metastatic HER2+ breast cancer

• Date :
• 0    
  0

Molecular profiling in early breast cancer

• Date :
• 0    
  0

Treating early-stage TNBC

• Date :
• 0    
  0

Future role of genomic tools in breast cancer treatment

• Date :
• 0    
  0

Treating HER2+ breast cancer with brain metastases

• Date :
• 0    
  0

HER2CLIMB-04: tucatinib + trastuzumab deruxtecan in HER2+ breast cancer

• Date :
• 0    
  0

Promising novel approaches to the treatment of TNBC

• Date :
• 0    
  0

44e Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse

• Date :
• 1853    
  0

14èmes Journées des Référentiels en Soins Oncologiques de support - AFSOS 2024

• Date :
• 1725    
  0

Post ASCO-ESMO 2024 Fédération Francophone de Cancérologie Digestive

• Date :
• 1332    
  0

45emes Journées de la Société Française de Sénologie et de Pathologie Mammaire - SFSPM 2024

• Date :
• 4499    
  0

Molecular Analysis for Precision Oncology Congress - MAP 2024

• Date :
• 1006    
  0